Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials

@article{Wang2016ComparativeEO,
  title={Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials},
  author={Runsheng Wang and Abhijit Dasgupta and Michael M. Ward},
  journal={Annals of the Rheumatic Diseases},
  year={2016},
  volume={75},
  pages={1152 - 1160}
}
OBJECTIVE To compare the efficacy of 20 non-steroidal anti-inflammatory drugs (NSAIDs) in the short-term treatment of ankylosing spondylitis (AS. [...] Key Method We included trials that reported efficacy at 2-12 weeks. Efficacy outcomes were the change in pain score and change in the duration of morning stiffness. We also examined the number of adverse events. We used Bayesian network meta-analysis to compare effects directly and indirectly between drugs. RESULTS We included 26 trials (66 treatment arms…Expand
Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials
TLDR
All NSAIDs were significantly more effective in reducing pain severity than placebo and etoricoxib was ranked as the most efficacious treatment for patients with AS, however, clinicians should take GI toxicity into account when prescribing NSAIDs. Expand
Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis
TLDR
Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated to support clinicians’ decision making, without taking out his/her autonomy when prescribing for an individual patient. Expand
New evidence on the management of spondyloarthritis
TLDR
Data indicate that TNF blockers are effective for treating peripheral arthritis, enthesitis and dactylitis, the typical manifestations of peripheral SpA, and the potential of IL-23 blockade for treatment of axial SpA needs to be further investigated. Expand
Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors
TLDR
In this observational cohort of established AS patients, there was no difference in baseline NSAIDs use between patients with and without indication for TNF-α inhibitors, but NSAID use changed frequently at individual patient level and was significantly associated with disease activity. Expand
The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
TLDR
It is proposed that Guluronic acid could be appropriate for management of AS because it had more notable safety characteristics identifying information than naproxen. Expand
Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis.
TLDR
NSAIDs could promote the clinical efficacy of treatment for ankylosing spondylitis by regulating serum levels of proinflammatory cytokines by regulating the levels of IL-6 and TNF-α. Expand
Emerging drugs for the treatment of axial spondyloarthritis
TLDR
The treatment of axial spondyloarthritis has been for nearly 15 years constricted to non-steroidal antirheumatic drugs and TNFα inhibitors but with the approval of secukinumab, a drug targeting the interleukin(IL)-17 axis became available. Expand
Evaluation of the e ffi cacy and safety of β-D-mannuronic acid in patients with ankylosing spondylitis : A 12-week randomized , placebo-controlled , phase I / II clinical trial
Objective: To evaluate the efficacy, safety and tolerability of β-D-mannuronic acid (M2000) in the treatment of ankylosing spondylitis (AS). Methods: The study was a 12-week randomized, double-blind,Expand
[The efficacy and safety of etoricoxib versus meloxicam in the treatment of patients with gonarthrosis].
TLDR
The efficacy of etoricoxib was significantly higher than that of meloxicam and the incidence of side effects was similar in both groups. Expand
Comparison of disease activity in patients with ankylosing spondylitis under TNFi or NSAID treatment, is there any difference? An observational study.
TLDR
In real world practice, ankylosing spondylitis patients under TNFi treatment show a better control of clinical symptoms than those under NSAIDs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey
TLDR
It is concluded that NSAIDs are effective in the management of inflammatory symptoms of many, but not all, patients with AS, and anti-tumor necrosis factor therapy may reduce the need for intensive long-term NSAID therapy in AS. Expand
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
TLDR
This study suggests that a 1 yr trial might be of optimum value compared to a 6 week assessment in order to define better the efficacy and tolerability of NSAIDs in ankylosing spondylitis. Expand
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug.
TLDR
The results of this study confirm the clinically relevant antiinflammatory effect of celecoxib at a 200-mg daily dosage, with significant improvement of both pain and function in patients with AS. Expand
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
TLDR
Etoricoxib at doses of 90 mg and 120 mg demonstrated superior efficacy compared with placebo over 6 weeks, and compared with naproxen over 1 year, demonstrating that etoricoxIB is generally safe, well-tolerated, and efficacious for the treatment of AS. Expand
Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.
TLDR
In this 12-week study, celecoxib 200 mg and 400 mg qd were efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. Expand
The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group.
TLDR
Acecl ofenac and indomethacin did not differ with respect to efficacy in the treatment of active AS, although aceclofenac was slightly better tolerated. Expand
A comparative study of Butacote and Naprosyn in ankylosing spondylitis.
TLDR
A double-blind, cross-over comparison of Naprosyn (naproxen) 750 mg daily and Butacote (enteric-coated phenylbutazone) 300 mg daily was carried out in a multi-centre trial, finding that both drugs significantly reduced morning stiffness. Expand
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs.
TLDR
Ankylosing spondylitis is a chronic inflammatory disease with a prevalence of 0.1–1.2%, and the therapeutic options are limited and confined to nonsteroidal antiinflammatory drugs (NSAIDs) and, if this treatment fails, to tumor necrosis factor (TNF) blockers. Expand
Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment
  • F. Huang, J. Gu, +5 authors Shi Le
  • Medicine
  • Current therapeutic research, clinical and experimental
  • 2014
TLDR
Celecoxib 200mg once daily is noninferior to diclofenac sustained release 75 mg once daily for pain treatment in Chinese patients with AS. Expand
A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis
TLDR
Diflunisal is an alternative capable of improving the painful stiffness associated with AS and, taking into account the possible haematological side effects, the use of other NSAIDs is stressed. Expand
...
1
2
3
4
5
...